Immunai

We are proud to expand our partnership with AstraZeneca in a multi-year collaboration aimed at optimizing clinical trials in oncology. By leveraging our AI-powered platforms, we’re working together to enhance clinical decision-making and accelerate drug development in oncology. Building on our shared success since 2022, this collaboration focuses on tackling some of the biggest challenges in clinical trials, like dose selection and patient responses, to bring new therapies to patients faster and more efficiently. Learn more about our new multi-year partnership here: https://lnkd.in/dFKTDczZ

Streamlining the journey from clinical trials to effective therapies is a mission we share with Teva Pharmaceuticals. Through our new multi-year collaboration, we're leveraging our AI-powered platforms—AMICA™ and the Immunodynamics Engine (IDE)™—to enhance decision-making in immunology and immuno-oncology trials. By focusing on understanding drug mechanisms, optimizing dose selection, and analyzing biomarkers, we're addressing key challenges to accelerate the development process. Learn more about our collaboration with Teva from Roman Kasianov in BioPharmaTrend.com: https://lnkd.in/d-Rcq_tK

Excited to share that Immunai’s AI platform, #AMICA, is nominated for AI Product of the Year at Geektime’s GeekAwards 2024!  Kudos to the Immunai team for pushing the boundaries of drug discovery and development! #GeekAwards2024 #AIInnovation 👉 Vote here and join us at the GeekAwards Summit on December 11th! https://lnkd.in/emRTcYFi

Inside each of our cells lies a unique story of immune response. On the Impact AI Podcast, our CEO @Noam Solomon spoke with Heather Couture, PhD about how our immune atlas leverages single-cell genomics and AI to drive more precise drug discovery. By mapping these cellular narratives, Immunai is charting a path toward therapies that don’t just treat but truly understand the patient. Listen to the full episode here: https://lnkd.in/dud9_RcM

🧬This month, we’re featuring David Brocks, as the second team member in our Inside Immunai spotlight series. David has been with us for over four years, now working as Director of Computational Biology. His journey at the company began thanks to a recommendation from his close friend, the late Elad Chomsky, who embodied our empathetic culture and the brilliant people who work here. Today, David is driven by those rare "eureka" moments that come from pushing boundaries in tech, and at Immunai, he leads the team responsible for building what he calls the "ChatGPT of the immune system." What keeps David going? Immunai’s self-optimizing culture. In his words, there hasn't been a year that hasn't been better than the one before. It’s the combination of our mission, the people, and the sense of appreciation that makes Immunai a special place to be. We love having you on our team, David! Fun fact: David enjoys playing ‘Soulsborne’ video games—drop a comment if you’re a gamer too! 🎮 You can join David, explore opportunities with Immunai here: https://lnkd.in/dri8bPpS #Biotech #MachineLearning #Immunology #Innovation #Healthcare

The reason drug approval rates are so low isn’t just because treatments are complex—it’s because every person’s immune system is different. With AI and our AMICA platform, we can finally navigate this complexity, using immune data to guide more precise and reliable drug development. Thanks to Michael Gibney for speaking to our CEO, Noam Solomon about how we’re moving beyond one-size-fits-all approaches to bring us closer to more effective treatments. More via PharmaVoice: https://lnkd.in/e6mn-K2r

AI-driven innovation is key to making cell therapies more accessible. Our CEO, Noam Solomon’s new byline in Pharma Executive Magazine examines how Immunai’s platforms are lowering costs and driving advancements in personalized medicine. By harnessing data, we're transforming the future of cell therapy and pushing the boundaries of what's possible. Discover how AI is paving the way for broader access to these life-saving treatments: https://lnkd.in/dH6xm42k"

Grateful to work with Shikha Nayar 🤩 and the whole Immunai team who bring their authentic, best selves to work every day!

🧬This week, we’re kicking off “Inside Immunai,” a monthly series highlighting the unique expertise of our team! We start by shining the spotlight on Shikha Nayar, our Systems Immunology Team Lead in our External Collaborations group. Shikha’s role involves extracting meaningful data from patient and preclinical studies and tackling challenging questions like why patients aren’t responding to certain drugs in clinical trials. Shikha empowers her team to find creative ways to answer tough questions and distill insights that are biologically meaningful and differentiated. One of the most exciting projects Shikha has worked on involves identifying novel targets in the IBD space. Having completed her Ph.D. in this field, she has seen the landscape evolve over the past decade and is excited to see how we can work with collaborators to move the needle forward. Outside of work, Shikha has a hidden talent—she's a passionate singer and has been performing with the Young New Yorkers Chorus for the last 10 years. Come watch a performance of hers this winter! 🎵 Shikha's enthusiasm for Immunai’s mission is palpable. Thank you for being an integral part of our team. You can explore opportunities with Immunai here: https://lnkd.in/dri8bPpS #Biotech #MachineLearning #Immunology #Innovation #Healthcare

Our CEO, Noam Solomon, recently welcomed Ruth Reader to our New York office, where they talked about the role of #AI in drug discovery. Their conversation, featured in today’s POLITICO’s Future Pulse newsletter, dives into our approach to mapping the immune system. We see it as a domino effect—where understanding one interaction sets off a chain reaction, revealing how each element in the immune system is interconnected. This view helps drugmakers anticipate how therapies will work in real-world scenarios, especially in complex conditions like cancer. Read POLITICO’s Future Pulse to learn more: https://lnkd.in/eHqwffeW